- Home
- MNMD vs GSL Comparison
MNMD vs GSL Comparison
Compare MNMD & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- GSL
- Stock Information
- Founded
- MNMD 2019
- GSL 2007
- Country
- MNMD United States
- GSL Greece
- Employees
- MNMD N/A
- GSL N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- GSL Marine Transportation
- Sector
- MNMD Health Care
- GSL Consumer Discretionary
- Exchange
- MNMD Nasdaq
- GSL Nasdaq
- Market Cap
- MNMD 960.2M
- GSL 1.0B
- IPO Year
- MNMD N/A
- GSL 2006
- Fundamental
- Price
- MNMD $11.01
- GSL $31.71
- Analyst Decision
- MNMD Strong Buy
- GSL Strong Buy
- Analyst Count
- MNMD 7
- GSL 1
- Target Price
- MNMD $26.71
- GSL $33.00
- AVG Volume (30 Days)
- MNMD 2.3M
- GSL 332.6K
- Earning Date
- MNMD 11-06-2025
- GSL 11-10-2025
- Dividend Yield
- MNMD N/A
- GSL 6.60%
- EPS Growth
- MNMD N/A
- GSL 19.05
- EPS
- MNMD N/A
- GSL 10.76
- Revenue
- MNMD N/A
- GSL $730,277,000.00
- Revenue This Year
- MNMD N/A
- GSL $4.58
- Revenue Next Year
- MNMD N/A
- GSL N/A
- P/E Ratio
- MNMD N/A
- GSL $2.96
- Revenue Growth
- MNMD N/A
- GSL 4.04
- 52 Week Low
- MNMD $4.70
- GSL $17.73
- 52 Week High
- MNMD $14.43
- GSL $33.08
- Technical
- Relative Strength Index (RSI)
- MNMD 41.39
- GSL 64.24
- Support Level
- MNMD $12.60
- GSL $30.68
- Resistance Level
- MNMD $14.43
- GSL $32.28
- Average True Range (ATR)
- MNMD 0.84
- GSL 0.69
- MACD
- MNMD -0.30
- GSL 0.36
- Stochastic Oscillator
- MNMD 11.52
- GSL 85.79
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.